2160.T Stock - GNI Group Ltd.
Unlock GoAI Insights for 2160.T
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $23.61B | $26.01B | $17.42B | $12.69B | $9.77B |
| Gross Profit | $18.04B | $22.43B | $14.74B | $11.09B | $8.23B |
| Gross Margin | 76.4% | 86.2% | 84.6% | 87.4% | 84.2% |
| Operating Income | $1.40B | $13.11B | $1.38B | $1.62B | $1.87B |
| Net Income | $977.66M | $8.09B | $388.82M | $1.07B | $1.26B |
| Net Margin | 4.1% | 31.1% | 2.2% | 8.4% | 12.9% |
| EPS | $21.96 | $169.50 | $8.19 | $22.72 | $28.96 |
GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial phase II and pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, it is involved in developing F351, which is in Phase II clinical trial for the treatment of liver fibrosis; and F573 that is in pre-clinical phase for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.
Visit WebsiteEarnings History & Surprises
2160.TEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 12, 2026 | — | — | — | — |
Q4 2025 | Nov 14, 2025 | $10.82 | $7.54 | -30.3% | ✗ MISS |
Q3 2025 | Aug 14, 2025 | $-109.70 | $-7.62 | +93.1% | ✓ BEAT |
Q2 2025 | May 15, 2025 | $27.86 | $-10.57 | -137.9% | ✗ MISS |
Q1 2025 | Feb 14, 2025 | $113.19 | $-6.53 | -105.8% | ✗ MISS |
Q4 2024 | Nov 14, 2024 | $13.04 | $19.48 | +49.4% | ✓ BEAT |
Q3 2024 | Aug 14, 2024 | $26.23 | $-22.57 | -186.0% | ✗ MISS |
Q2 2024 | May 15, 2024 | $20.90 | $29.17 | +39.6% | ✓ BEAT |
Q1 2024 | Feb 14, 2024 | $-9.79 | $122.89 | +1355.3% | ✓ BEAT |
Q4 2023 | Nov 14, 2023 | $26.25 | $11.68 | -55.5% | ✗ MISS |
Q3 2023 | Aug 14, 2023 | $105.37 | $34.99 | -66.8% | ✗ MISS |
Q2 2023 | May 15, 2023 | — | $-0.06 | — | — |
Q1 2023 | Feb 15, 2023 | $-8.00 | $-13.05 | -63.1% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | $10.30 | $8.42 | -18.3% | ✗ MISS |
Q3 2022 | Aug 15, 2022 | — | $6.86 | — | — |
Q2 2022 | May 16, 2022 | — | $7.40 | — | — |
Q1 2022 | Feb 14, 2022 | $0.77 | $-4.80 | -725.0% | ✗ MISS |
Q4 2021 | Nov 15, 2021 | — | $7.44 | — | — |
Q3 2021 | Aug 13, 2021 | — | $10.78 | — | — |
Q2 2021 | May 17, 2021 | — | $9.50 | — | — |
Latest News
Frequently Asked Questions about 2160.T
What is 2160.T's current stock price?
What is the analyst price target for 2160.T?
What sector is GNI Group Ltd. in?
What is 2160.T's market cap?
Does 2160.T pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to 2160.T for comparison